专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US06624202B2 Inhibitors of copper-containing amine oxidases 失效
标题翻译：含铜胺氧化酶的抑制剂
公开(公告)号：US06624202B2
公开(公告)日：2003-09-23
申请号：US09898003
申请日：2001-07-05
申请人： David John Smith , Markku Jalkanen , Ferenc Fülöp , László Lázár , Zsolt Szakonyi , Gábor Bernáth
发明人： David John Smith , Markku Jalkanen , Ferenc Fülöp , László Lázár , Zsolt Szakonyi , Gábor Bernáth
IPC分类号： A61K3115
CPC分类号： A61K31/131 , A61K31/14 , A61K31/15 , A61K31/40 , A61K31/445 , A61K31/472
摘要： The present invention is directed to hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The compounds have the general formula: or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R1 to R8 and X are as defined herein.
摘要翻译：本发明涉及用作通常称为氨基脲敏感性胺氧化酶（SSAO）的含铜胺氧化酶的抑制剂的肼基化合物，包括称为血管粘附蛋白-1（VAP-1）的人SSAO。这些SSAO抑制剂具有用于治疗病症和疾病的药物的治疗用途，包括但不限于许多炎性病症和疾病（特别是慢性炎症病症如慢性关节炎，炎性肠病和慢性皮肤皮肤病），相关疾病到碳水化合物代谢和脂肪细胞分化或功能和平滑肌细胞功能异常以及血管疾病。所述化合物具有以下通式：或其药学上可接受的溶剂合物，水合物或盐，其中R 1至R 8和X如本文所定义。

12. 发明申请

US20100209942A1 NEW BIOMARKER FOR MONITORING DEVELOPMENT OF DISEASES AND ASSESSING THE EFFICACY OF THERAPIES 审中-公开
标题翻译：用于监测疾病发展和评估治疗效果的新生物标志物
公开(公告)号：US20100209942A1
公开(公告)日：2010-08-19
申请号：US12679785
申请日：2008-10-15
申请人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
发明人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
IPC分类号： G01N33/573
CPC分类号： G01N33/57484 , G01N2333/70596 , G01N2800/245 , G01N2800/324 , G01N2800/56
摘要： The invention concerns a method for monitoring the development of a disease in a patient, or for assessing the efficacy of a cytokine therapy or a statin therapy in a patient, in which methods CD73 in a tissue fluid drawn from said patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.
摘要翻译：本发明涉及用于监测患者疾病发展或用于评估患者中细胞因子疗法或他汀类药物治疗的功效的方法，其中从所述患者中抽出的组织液中的CD73用作生物标志物。本发明还涉及用于测定从个体组织液中抽取的样品中CD73蛋白质的方法。

13. 发明授权

US06887698B2 Glucuronyl C5-epimerase, DNA encoding the same and uses thereof 失效
标题翻译：葡糖醛酸C5-差向异构酶，编码其的DNA及其用途
公开(公告)号：US06887698B2
公开(公告)日：2005-05-03
申请号：US10005647
申请日：2001-12-07
申请人： Markku Jalkanen , Kamel El Darwish , Ulf Lindahl , Jin-ping Li
发明人： Markku Jalkanen , Kamel El Darwish , Ulf Lindahl , Jin-ping Li
IPC分类号： C12N15/09 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/90 , C12N15/61
CPC分类号： C12N9/90 , C12Y501/03012
摘要： The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.
摘要翻译：本发明涉及新型纯化的小鼠C5-差向异构酶，其片段，编码它们的核酸及其重组生产。本发明还涉及这种差向异构酶的片段，特别是可用于融合蛋白构建体以增强重组产生的异源差向异构酶的活性的N-末端片段。

14. 发明授权

US08119651B2 Compositions useful especially for treatment or prevention of metabolic syndrome 失效
标题翻译：适用于治疗或预防代谢综合征的组合物
公开(公告)号：US08119651B2
公开(公告)日：2012-02-21
申请号：US12060533
申请日：2008-04-01
申请人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
发明人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
IPC分类号： A61K31/51
CPC分类号： A61K31/51 , A23L33/15 , A23V2002/00 , Y10S514/866 , A23V2250/7042 , A23V2200/332 , A23V2200/324 , A23V2200/3262 , A23V2200/328
摘要： This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.
摘要翻译：本发明涉及一种用于治疗或预防代谢综合征的方法及其在个体中产生的疾病或病症，其中向所述个体施用有效量的胺氧化酶抑制剂。此外，本发明涉及一种抑制胺氧化酶或用于治疗或预防有益于个体中胺氧化酶抑制的疾病或病症的方法，其中给予维生素B1，其衍生物，其前体或代谢物给个人最后，本发明涉及包含与食品组合的胺氧化酶抑制剂的食品，包含胺氧化酶抑制剂与液体，固体或半固体载体组合的食品添加剂。

15. 发明申请

US20070191408A1 Compositions useful especially for treatment or prevention of metabolic syndrome 审中-公开
标题翻译：适用于治疗或预防代谢综合征的组合物
公开(公告)号：US20070191408A1
公开(公告)日：2007-08-16
申请号：US11488914
申请日：2006-07-19
申请人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
发明人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
IPC分类号： A61K31/51 , A23L1/302
CPC分类号： A61K31/51 , A23L33/15 , A23V2002/00 , A23V2250/7042 , A23V2200/332 , A23V2200/324 , A23V2200/3262 , A23V2200/328
摘要： The present invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual in which an effective amount of an amine oxidase enzyme inhibitor is administered to the individual. The invention also relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual in which a vitamin B1, its derivative, its precursor or metabolite is administered to the individual. In addition, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, as well as a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.
摘要翻译：本发明涉及一种用于治疗或预防代谢综合征的方法，以及在其中向个体施用有效量的胺氧化酶抑制剂的个体中由此产生的疾病或病症。本发明还涉及一种用于抑制胺氧化酶或用于治疗或预防受益于个体中胺氧化酶的抑制的疾病或病症的方法，其中将维生素B1，其衍生物，其前体或代谢物施用于个人。此外，本发明涉及包含与食品组合的胺氧化酶抑制剂的食品，以及包含胺氧化酶抑制剂与液体，固体或半固体载体组合的食品添加剂。

16. 发明申请

US20070093433A1 Aminoglycoside antibiotics for use as vap-1/ssao inhibitors 审中-公开
标题翻译：用作vap-1 / ssao抑制剂的氨基糖苷类抗生素
公开(公告)号：US20070093433A1
公开(公告)日：2007-04-26
申请号：US10579791
申请日：2004-12-17
申请人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
发明人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
IPC分类号： A61K31/7034
CPC分类号： A61K31/7048 , A61K31/7034
摘要： The present invention concerns the use of a compound comprising one or more sugar moieties, which optionally are aminosubstitutes, and possibly other moieties, wherein said compound is a molecule comprising at least two aminosubstituents, said aminosubstituents being primary, secondary or tertiary amino groups, wherein said aminosubstituents are either attached to one single sugar moiety or attached to several sugar moieties or other moieties of the molecule, or to chains connecting two moieties or to chains being substituents to the molecule, for the manufacture of a pharmaceutical preparation useful as an agent capable of influencing an amine oxidase enzyme activity, more particularly inhibiting VAP-1/SSAO activity. The preferred compounds are aminoglycoside antibiotics, e.g., streptomycin, netilmicin, geneticin, gentamicin, puromycin, tobramycin and amikacin. The preferred conditions to be treated are inflammatory diseases or conditions, diseases related to carbohydrate metabolism, diseases related to aberrations in adipocyte differentiation or function or smooth muscle cell function, and vascular diseases.
摘要翻译：本发明涉及包含一个或多个糖部分的化合物（其任选为氨基化合物）以及可能的其它部分的用途，其中所述化合物是包含至少两个氨基取代基的分子，所述氨基取代基是伯，仲或叔氨基，其中所述氨基取代基连接到一个单个糖部分或连接到该分子的几个糖部分或其它部分，或连接到分子的两个部分或连接于链的取代基的链，用于制备可用作药剂的药物制剂影响胺氧化酶活性，更特别地抑制VAP-1 / SSAO活性。优选的化合物是氨基糖苷类抗生素，例如链霉素，净霉素，遗传霉素，庆大霉素，嘌呤霉素，妥布霉素和阿米卡星。待治疗的优选条件是炎性疾病或病症，与碳水化合物代谢有关的疾病，与脂肪细胞分化或功能或平滑肌细胞功能异常有关的疾病和血管疾病。

17. 发明授权

US5851993A Suppression of tumor cell growth by syndecan-1 ectodomain 失效
标题翻译：通过syndecan-1胞外结构域抑制肿瘤细胞生长
公开(公告)号：US5851993A
公开(公告)日：1998-12-22
申请号：US488199
申请日：1995-06-07
申请人： Markku Jalkanen , Marku Mali
发明人： Markku Jalkanen , Marku Mali
IPC分类号： A61K38/00 , A61K20060101 , A61K38/17 , A61P35/00 , C07K14/705 , A61K38/16 , C07K14/47
CPC分类号： C07K14/70596 , A61K38/00
摘要： Methods of reducing tumor growth, including the suppression of tumor growth in a patient, are provided by the administration of efficacious levels of syndecan ectodomain to the extracellular environment of the tumor cell. Pharmaceutically acceptable compositions of syndecan are also provided.
摘要翻译：通过将有效水平的syndecan胞外域施用于肿瘤细胞的细胞外环境来提供减少肿瘤生长的方法，包括抑制患者的肿瘤生长。还提供了联合胶囊的药学上可接受的组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式